Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma
Public ClinicalTrials.gov record NCT02528214. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Severe Steroid Dependent Asthma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary Objective: To evaluate the efficacy of dupilumab, compared with placebo, for reducing the use of maintenance oral corticosteroids (OCS) in participants with severe steroid-dependent asthma. Secondary Objectives: * To evaluate the safety and tolerability of dupilumab. * To evaluate the effect of dupilumab in improving participants-reported outcomes. * To evaluate dupilumab systemic exposure and the incidence of treatment-emergent antidrug antibodies.
Study identification
- NCT ID
- NCT02528214
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 210 participants
Conditions and interventions
Conditions
Interventions
- Dupilumab Drug
- Placebo Drug
- Oral corticosteroid therapy (prednisone/prednisolone) Drug
- Inhaled corticosteroid (ICS) therapy Drug
- Albuterol/Salbutamol Drug
- Levalbuterol/Levosalbutamol Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 14, 2015
- Primary completion
- Sep 19, 2017
- Completion
- Nov 12, 2017
- Last update posted
- Sep 30, 2019
2015 – 2017
United States locations
- U.S. sites
- 8
- U.S. states
- 4
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 840022 | Los Angeles | California | 90048 | — |
| Investigational Site Number 840014 | Rolling Hills Estates | California | 90274 | — |
| Investigational Site Number 840002 | St Louis | Missouri | 63110 | — |
| Investigational Site Number 840010 | Pittsburgh | Pennsylvania | 15213 | — |
| Investigational Site Number 840062 | Amarillo | Texas | 79106 | — |
| Investigational Site Number 840070 | McKinney | Texas | 75069 | — |
| Investigational Site Number 840128 | McKinney | Texas | 75071 | — |
| Investigational Site Number 840118 | Plano | Texas | 75093 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 72 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02528214, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 30, 2019 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02528214 live on ClinicalTrials.gov.